REGN-EB3: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-020-01452-3
Abstract: REGN-EB3 (INMAZEB ® , Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during… read more here.
Keywords: eb3; first approval; regn eb3; ebola virus ... See more keywords
A drug‐disease model for predicting survival in an Ebola outbreak
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13383
Abstract: REGN‐EB3 (Inmazeb) is a cocktail of three human monoclonal antibodies approved for treatment of Ebola infection. This paper describes development of a mathematical model linking REGN‐EB3’s inhibition of Ebola virus to survival in a non‐human… read more here.
Keywords: time; disease; regn eb3; survival ... See more keywords